Tilray Brands (TLRY) Asset Utilization Ratio (2018 - 2026)

Tilray Brands' (TLRY) quarterly Asset Utilization Ratio came in at 0.42 in Q2 2026, up 1.1% on a QoQ basis from 0.41 in Q1 2026.

Tilray Brands (TLRY) Asset Utilization Ratio (2018 - 2026) Analysis & Trends

Tilray Brands (TLRY) has 9 years of Asset Utilization Ratio data on file, last reported at 0.42 in Q2 2026.

Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.42 in Q2 2026, while the trailing twelve-month figure through May 2026 was 0.42 (changed N/A YoY) and the FY2026 annual result came in at 0.42, up 59.41% from the prior year.
Asset Utilization Ratio climbed to 0.42 in Q2 2026, from 0.41 in the prior quarter.
In the past five years, Asset Utilization Ratio ranged from a high of 0.42 in Q2 2026 to a low of 0.11 in Q1 2022.
A 5-year average of 0.21 and a median of 0.17 in 2023 frame the typical range for Asset Utilization Ratio.
Annual changes were most pronounced in 2022 — Asset Utilization Ratio increased 8.56% — and 2025, when it surged 108.79%.
Tracing TLRY's Asset Utilization Ratio over 5 years: stood at 0.11 in 2022, then soared by 47.33% to 0.16 in 2023, then advanced by 22.28% to 0.2 in 2024, then surged by 104.16% to 0.4 in 2025, then advanced by 3.83% to 0.42 in 2026.
The last three Asset Utilization Ratio figures came in at 0.42 (Q2 2026), 0.41 (Q1 2026), and 0.4 (Q4 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Haleon	43.85 Bn	42.88 Bn	-	-
2	Teva Pharmaceutical Industries	43.02 Bn	39.37 Bn	2.15 Bn	0.43
3	Zoetis	31.47 Bn	29.79 Bn	1.05 Bn	0.63
4	Takeda Pharmaceutical	28.59 Bn	22.79 Bn	5.10 Bn	0.47
5	United Therapeutics	22.20 Bn	19.53 Bn	683.80 Mn	0.45
6	Viatris	18.76 Bn	17.87 Bn	1.46 Bn	0.41
7	Neurocrine Biosciences	15.45 Bn	15.06 Bn	935.80 Mn	0.66
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	0.37
9	Dr Reddys Laboratories	10.10 Bn	9.94 Bn	-	-
10	Tilray Brands	519.72 Mn	285.09 Mn	90.52 Mn	0.42

Download Data